Programme

Presentation synopsis:

Are new antiretroviral treatments increasing the risks of clinical obesity?

In HIV-negative people, clinical obesity is associated with a wide range of clinical consequences: for example, Alzheimer’s disease, adverse birth outcomes and cardiovascular disease.  In HIV clinical trials and cohort studies, the risk of weight gain and clinical obesity is higher for women, black people, and those taking integrase inhibitors - in particular dolutegravir and bictegravir.  The use of TDF (but not TAF) is associated with weight loss, which could compensate for the effects of integrase inhibitors.

 

In this overview talk, new results from the NAMSAL and ADVANCE trials will be presented. These trials included treatment of black women with dolutegravir and tenofovir alafenamide. This combination is expected to show the greatest risk of clinical obesity. 

Speaker biography:

Andrew Hill graduated from Oxford University, and then gained his PhD from the University of Amsterdam.  He has worked on HIV clinical trials for over 20 years. He is currently a Senior Visiting Research Fellow at Liverpool University, specialising in drug safety and access to medicine.

He is also a consultant to the World Health Organisation and the Clinton Foundation.


Registration

Registration is open

Second Announcement

Take a look

Call for abstracts

Submissions are closed